戻る Agenda
How Mechanism of Action-Driven Development Can Address the Covid-19 Challenge
Session Chair(s)
Martine Zimmermann, PharmD
Senior Vice President, Head of Global Regulatory Affairs
Ipsen , France
How Mechanism of Action-Driven Development Can Address the Covid-19 Challenge
Speaker(s)
Experience In COVID-19 Development From The Rare Disease Developer Perspective
Martine Zimmermann, PharmD
Ipsen , France
Senior Vice President, Head of Global Regulatory Affairs
Repurposing Existing Drugs For Covid-19: Perspectives From A Large Pharma
Linda Jack, PhD
Roche Products Ltd., United Kingdom
Global Regulatory Franchise Head, Infectious Disease, Rheumatology and Gastroimm
How Mechanism Of Action-Driven Development Can Address The COVID-19 Challenge
Marco Cavaleri, PhD
European Medicines Agency, Netherlands
Head of Health Threats and Vaccines Strategy